Have you registered already? This Wednesday, we are continuing our webinar series on hit identification strategies at Evotec. Please register now for episode 4 "The Role of Structural Insights in Drug Discovery" Join as as Dr. Jay Bertrand, Vice President, Head of Global Structural Biology and Evotec's Princeton Site Head, discusses the evolution of structural support to drug discovery projects, and provides insight into choosing the right protein for structural analysis. He will also share case studies on the application of X-ray and cryo-EM to obtain compound-bound protein structures. https://hubs.ly/Q02NhCZR0
Info
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
- Website
-
http://www.evotec.com
Externer Link zu Evotec
- Branche
- Biotechnologieforschung
- Größe
- 5.001–10.000 Beschäftigte
- Hauptsitz
- Hamburg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- CNS, Oncology, Pain, Neurosciences, Inflammation, Metabolic disease, Infection, Respiratory diseases, Drug-Discovery, CMC, IND enabling und Drug Development
Orte
-
Primär
Manfred Eigen Campus
Essener Bogen 7
Hamburg, 22419, DE
Beschäftigte von Evotec
Updates
-
Interested in learning more about bottlenecks in the #biologics market? Welcome to our mini-series covering this topic. In this first article we discuss limitations in #biomanufacturing and look at key challenges and how they can be overcome. https://hubs.ly/Q02MRLLn0 #biotherapeutics #ResearchNeverStops
-
-
PanHunter provides multiple interactive analyses for scientists looking to gain deeper insights into their projects. Do you want to know which biological pathways and gene sets are significantly regulated by your treatment? Which proteins physically interact with your target? Are there other treatments or diseases that induce regulation similar to yours? Find out how PanHunter answers these questions! https://hubs.ly/Q02Mv9L10 #researchneverstops #panhunter #omics #transcriptomics #proteomics #dataanalysis #datascience
-
-
Missed our live webinars on “Mastering Quality by Design”? Catch up on-demand! Evotec’s Quality by Design webinar series is now available to stream on-demand. Dive into the sessions at your convenience and gain valuable insights into QbD’s role in enhancing pharmaceutical quality. https://hubs.ly/Q02LpDCw0. #drugdevelopment #QualityByDesign
-
-
Unlocking GPCR Secrets with GCI... Dr. Edoardo Fabini, our Biophysics lead, will reveal how GCI is revolutionizing small molecule studies and how this impacts fragment screening & GPCR drug discovery. Where? At the GCI/ITC EMEA Community Meeting, organised by Malvern Panalytical. Find everything you need to know here: https://hubs.ly/Q02N07vC0 See you there! #MembraneProteins #GCI #GPCR
-
-
Speed up your drug discovery with Cyprotex! Our high throughput ADME services deliver rapid & reliable data for you to make informed decisions quickly. Reach out to us to find out more about our customizable protocols, industry-validated methods, ADME consultancy service, and < 72 hr turnaround for key assays on your regular screening contracts at [email protected] Learn more: https://hubs.ly/Q02M_Q6V0 #researchneverstops #adme #cyprotex
-
Read our new blog article and learn more about Evotec's end-to-end capabilities for the synthesis, purification, isolation, and quality control of complex modified Oligonucleotides, such as ASOs and siRNAs. We can support Oligonucleotide drug discovery and development projects from the earliest phases of discovery, such as the generation of screening libraries, up to the selection of a preclinical development candidate followed by manufacture and release of material to support initial preclinical development studies. Learn more in our recent blog article- https://hubs.ly/Q02Kch2C0
-
-
Join us us at the EFMC International Symposium on Medicinal Chemistry in Rome next week! Mafalda Pagano, our medicinal chemistry expert, will be presenting a poster on Application of early dose to man calculations to guide the selection of a selective tool compound for probing the role of lysophosphatidic acid type 2 receptor antagonists in idiopathic pulmonary fibrosis on on Monday, 2 September from 17:30 to 19:00. Fabrizio Micheli, VP Medicinal Chemistry, will be attending as part of the local organizing committee. Learn more about the event and contact us to arrange a meeting here- https://hubs.ly/Q02MRHBZ0 #MedicinalChemistry #EFMC-ISMC2024
-
-
Missed our live webinar on case study ID11916? Catch up on demand! Discover how a poorly soluble drug was turned into a high-performing formulation in just six weeks, even with scarce API availability. Our experts, Fabrizio Fina and Zsolt Lendvai, present the fascinating case study of ID11916. They explain how they transformed its initial water-insoluble state into an innovative oral formulation, accelerating its path to the human clinical trial phase. Don't miss out on this insightful session! https://hubs.ly/Q02Kch-B0 #bioavailability #preformulation #earlyformulation #drugdevelopment
-
-
Join Us at Eurotox 2024! We are thrilled to invite you to two exciting events hosted by Evotec and Cyprotex at Eurotox 2024! Don't miss these opportunities to gain valuable insights and network with industry experts. Industry Hosted Session Topic: Navigating the Preclinical Development of Antibody Drug Conjugates (ADCs) Focus: Toxicology De-Risking Strategies for Enabling Personalized Medicine Date & Time: Monday, 9 September 2024, 12:00-13:00 Presenters: Dario Salerno, Senior Manager, Safety Assessment, and Giulia Iannoto, Immunotoxicologist, Safety Assessment Session Highlights: - Explore the complexities of ADCs, biopharmaceutical molecules designed to target cancer cells. - Understand the unique challenges in nonclinical safety assessment of ADCs. - Learn about the science-based approach to safety assessment and current regulatory guidelines. - Discover our recent case study and experiences with ADCs. Poster Presentation Title: Multiparametric In Vitro Assays Combined with High-Throughput RNA Sequencing for Cardiotoxicity Risk Assessment and Mechanistic Insight (#916) Date and time: Monday, 9 September 2024, 9:30am Presenter: Samantha Llewellyn, Associate Principal Scientist - Cyprotex Join us to delve into innovative methodologies for cardiotoxicity risk assessment and gain mechanistic insights through high-throughput RNA sequencing. Don't miss these sessions to stay at the forefront of toxicology and preclinical development. We look forward to seeing you there! #Eurotox2024 #ADCs #Toxicology #PreclinicalDevelopment #Cardiotoxicity #PersonalizedMedicine https://hubs.ly/Q02L3WNC0
-